Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KGA-2727

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Macula Densa SGLT1-NOS1-Tubuloglomerular Feedback Pathway, a New Mechanism for Glomerular Hyperfiltration during Hyperglycemia.
  • J. Zhang, J. Wei, +7 authors R. Liu
  • Journal of the American Society of Nephrology…
  • 2019
    • Corpus ID: 76662419
BACKGROUND Glomerular hyperfiltration is common in early diabetes and is considered a risk factor for later diabetic nephropathy… Expand
2019
2019
Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice.
Recent studies demonstrated that sodium-glucose co-transporter 1 (SGLT1) is associated with human ischemic cardiomyopathy… Expand
Highly Cited
2015
Highly Cited
2015
Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
GSK-1614235 and KGA-2727 are potent, selective inhibitors of the SGLT1 sodium-dependent glucose transporter. Nonclinical (KGA… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2013
2013
SGLT-2 inhibitors: the glucosuric antidiabetics
Despite availability of a number of oral antidiabetics, a sizeable population of diabetics remains uncontrolled. Thus there is… Expand
Highly Cited
2012
Highly Cited
2012
KGA-2727, a Novel Selective Inhibitor of a High-Affinity Sodium Glucose Cotransporter (SGLT1), Exhibits Antidiabetic Efficacy in Rodent Models
The high-affinity sodium glucose cotransporter (SGLT1) plays a critical role in glucose absorption from the gastrointestinal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE